These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 20074016

  • 1. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 2. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Feb; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 3. Tyrosine kinase inhibitors to treat liver cancer.
    Huynh H.
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):13-26. PubMed ID: 20128706
    [Abstract] [Full Text] [Related]

  • 4. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 5. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA, Galle PR.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):615-29. PubMed ID: 20374038
    [Abstract] [Full Text] [Related]

  • 6. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

  • 7. Systemic therapies in hepatocellular carcinoma.
    Wörns MA, Weinmann A, Schuchmann M, Galle PR.
    Dig Dis; 2009 May 01; 27(2):175-88. PubMed ID: 19546557
    [Abstract] [Full Text] [Related]

  • 8. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
    Frau M, Biasi F, Feo F, Pascale RM.
    Mol Aspects Med; 2010 Apr 01; 31(2):179-93. PubMed ID: 20176048
    [Abstract] [Full Text] [Related]

  • 9. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L, Kubicka S.
    Onkologie; 2008 Oct 01; 31(10):550-5. PubMed ID: 18854656
    [Abstract] [Full Text] [Related]

  • 10. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 11. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug 01; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 12. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 01; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 13. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Finn RS.
    Clin Cancer Res; 2010 Jan 15; 16(2):390-7. PubMed ID: 20068087
    [Abstract] [Full Text] [Related]

  • 14. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M, Ueshima K.
    Oncology; 2010 Jul 15; 78 Suppl 1():154-66. PubMed ID: 20616599
    [Abstract] [Full Text] [Related]

  • 15. Pathogenesis of hepatocellular carcinoma and molecular therapies.
    Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM.
    Curr Opin Gastroenterol; 2009 May 15; 25(3):186-94. PubMed ID: 19387255
    [Abstract] [Full Text] [Related]

  • 16. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L, Santoro A.
    Dig Liver Dis; 2010 Jul 15; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [Abstract] [Full Text] [Related]

  • 17. [Hepatocellular carcinoma].
    Kondo S, Ueno H, Morizane C, Okusaka T.
    Gan To Kagaku Ryoho; 2010 Jul 15; 37(7):1219-23. PubMed ID: 20647702
    [Abstract] [Full Text] [Related]

  • 18. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
    Kudo M.
    Dig Dis; 2011 Jul 15; 29(3):273-7. PubMed ID: 21829017
    [Abstract] [Full Text] [Related]

  • 19. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 20. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB.
    Curr Opin Investig Drugs; 2007 Dec 14; 8(12):1009-21. PubMed ID: 18058572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.